FIGURE 11.
CC-220 inhibits SLE plasmablast differentiation and Ab production from BAFF activated B cells. Total B cells isolated from HCs and SLE patients were treated with CC-220 (10 nM) for 1 h at 37°C before adding IL-2/IL-21/BAFF and culturing for 5 d. (A) Induced differentiated plasmablasts defined as percent CD20loCD38hi cells of total CD19+ B cells. IgG (B) and IgM (C) production after 5 d in culture. (D) Viability of cells posttreatment with CC-220 as a percent of the corresponding vehicle control (HC, SLE). Graphs shown are plotted as the mean percent of the corresponding vehicle control (HC or SLE B cells in the absence of CC-220) ± SEM. n = 13 HCs, n = 7 SLE patients. ** p < 0.005, ****p < 0.0001 for CC-220–treated cells versus their corresponding vehicle-treated cells (HC or SLE). NS, not significant comparing CC-220–treated HC versus CC-220–treated SLE cells.